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Abstract
Parasites have developed a variety of physiological functions necessary for their survival within the specialized environment of the host.
Using metabolic systems that are very different from those of the host, they can adapt to low oxygen tension present within the host animals.
Most parasites do not use the oxygen available within the host to generate ATP, but rather employ systems anaerobic metabolic pathways.
The enzymes in these parasite-specific pathways are potential targets for chemotherapy. Cyanide-insensitive trypanosome alternative oxidase
(TAO) is the terminal oxidase of the respiratory chain of long slender bloodstream forms of the African trypanosome, which causes sleeping
sickness in human and nagana in cattle. TAO has been targeted for the development of anti-trypanosomal drugs because it does not exist in
the host. Recently, we found the most potent inhibitor of TAO to date, ascofuranone, a compound isolated from the phytopathogenic fungus,
Ascochyta visiae. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The survival of parasites is dependent on that of the host.
It is thought that parasites originated from non-parasitic
ancestors and adapted to the environment in the host,
evolving host and organ specificities. Parasites adapt to a
low oxygen tension environment in the host using metabolic
pathways that are very different from those of the host
animals. In such systems, parasite mitochondria undergo
significant changes in their morphology and composition
during development and environmental adaptation [1].
These unique aspects of parasite mitochondria may be
promising targets for chemotherapy.
Recently, we isolated a novel compound, nafuredin, from
Aspergillus niger [2]. Nafuredin inhibits NADH-fumarate
reductase (complexes I + II) activity, a unique anaerobic
electron transport system in helminth mitochondria. This
compound is active at nanomolar concentrations. It com-
petes for the quinone-binding site in complex I and shows
high selective toxicity for the helminth enzyme. Moreover,
nafuredin exerts anti-helminthic activity against Haemon-
chus contortus in in vivo trials in sheep. These findings
show that the parasite mitochondrial respiratory chain is a
worthwhile target for chemotherapy.
In this review, we describe an additional novel inhibitor
of parasite mitochondrial function, ascofuranone. This com-
pound blocks the cyanide-insensitive terminal oxidase of
Trypanosoma brucei brucei mitochondria, an enzyme also
known as trypanosome alternative oxidase (TAO) [3]. In
addition, this compound inhibits trypanosomal growth in
heavily infected mice, and is, therefore a good lead for the
development of new treatments for African trypanosomiasis
[4]. Also, this validates TAO as a good target for the
development of anti-trypanosomal chemotherapeutic agents.
2. African trypanosome
2.1. African trypanosomiasis
African trypanosomes are protozoan parasites responsi-
ble for sleeping sickness and nagana, diseases mediated by
tsetse flies. Trypanosome infections are not only a problem
in humans, but they are also a major issue for animals,
livestock in particular, and are a principle issue in the
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African food supply problem. Trypanosomes escape elimi-
nation by the host immune system by varying their cell
surface antigens, including repeated changes of the variant
surface glycoprotein (VSG), a glycolipid-anchored glyco-
protein [5]. Therefore, it is quite difficult to produce
effective vaccines against them, and anti-trypanosomal che-
motherapy is a major strategy against this African trypano-
somiasis [6].
The two most commonly used chemotherapeutic com-
pounds against trypanosomiasis are suramin and pen-
tamidine. These compounds are effective during the hema-
tological stage of the disease. Melarsoprol and a-difluor-
omethylornithine (DFMO), on the other hand, are used in
late-stage disease. However, the first two agents are inef-
fective at eradicating the parasite if it already has sur-
mounted the blood–brain barrier, and the latter two
frequently have fatal side effects [7]. Clearly, research and
development of new drugs for the treatment of African
trypanosomiasis is urgently needed.
2.2. Mitochondria of T. b. brucei
T. b. brucei, the causative agent of nagana in cattle, is
closely related to T. b. rhodesiense and T. b. gambiense,
which cause sleeping sickness in humans. We have been
studying mitochondria of T. b. brucei as a target for chemo-
therapy because of its unique metabolic properties. Flag-
ellates generally have one mitochondrion per cell, which
contains RNA-editing kinetoplast DNA. Also, previous
studies have shown that the structure and function of T. b.
brucei mitochondria change markedly during their life cycle
(Table 1) [8].
In the procyclic forms of T. b. brucei found in the tsetse
fly vector, ATP is synthesized by oxidative phosphorylation,
and the mitochondria possess developed cristae containing
Table 1
Change of energy metabolism during life cycle in T. b. brucei
Host stage Tsetse procyclic Human trypomastigote
LS SS
Mitochondria active inactive active
TCA cycle +  +




ATP synthesis mitochondria glycosome mitochondria
LS: long slender form, SS: short stumpy form.
Fig. 1. Glucose metabolism in bloodstream form of T. b. brucei under aerobic and anaerobic conditions. (1) Glycerol kinase, (2) glycerol-3-phosphate
dehydrogenase, (3) cyanide-insensitive quinol ozidase (TAO). AF and glycerol inhibit TAO and glycerol kinase, respectively. Modified from Ref. [26].
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the respiratory chain and ATP synthetase systems. In con-
trast, in the long slender (LS) bloodstream form, which lives
in the host mammal’s blood, energy metabolism occurs
mostly by the glycolytic pathway in a specific organelle
called the glycosome (Fig. 1) [9]. Glycosomes contain a
100-fold higher concentration of glycolytic enzymes than
the cytoplasm of typical cells, and the glycolytic reaction
proceeds at a high efficiency. Further, mitochondria of the
LS form contain no cytochrome systems and do not synthe-
size ATP by oxidative phosphorylation. Rather, the mito-
chondrial cyanide-insensitive glycerol-3-phosphate oxidase
system is used to re-oxidize of NADH produced in the
glycolytic pathway (Fig. 2). Specifically, this system oxi-
dizes glycerol-3-phosphate produced in the glycosomes
using an electron transport system in the inner mitochon-
drial membrane consisting of glycerol-3-phosphate dehy-
drogenase, ubiquinone, and TAO [10]. Because the trypa-
nosome glycerol-3-phosphate oxidase system does not exist
in the host, it has attracted attention as a target for trypano-
cides. Indeed, suramin may act by inhibiting the glycerol-3-
phosphate oxidation system, although the mechanism is not
certain at this time [11].
Under anaerobic conditions, or in the presence of
a respiratory inhibitor such as salicylhydroxamic acid
(SHAM), glycerol-3-phosphate accumulates inside the gly-
cosome, and this is converted to glycerol by a reverse action
of glycerol kinase [9]. In other animals, this enzyme functions
almost exclusively in the forward direction, producing glyc-
erol-3-phosphate from ATP and glycerol. This new anaerobic
glycolytic pathway leads to the synthesis of 1 mol of ATP and
1 mol of glycerol. In this way, 1 mol of glucose is dismutated
into equimolar amounts of pyruvate and glycerol, with a net
synthesis of 1mol of ATP, even under anaerobic conditions or
in the presence of respiratory inhibitors (Fig. 1). Therefore,
inhibition of cyanide-insensitive respiration alone is not
sufficient to kill the parasite, and the trypanosome can survive
as long as glycerol does not accumulate in the medium.
However, once the concentration of glycerol in the medium
becomes several millimolar, mass action causes the enzyme
to reverse and produce glycerol-3-phosphate from glycerol
and anaerobic glycolysis in the glycosome stops. In fact,
simultaneous administration of SHAM and glycerol leads to
an immediate lysis and disappearance of the parasite from the
blood [12].
3. Effect of ascofuranone
3.1. Effect of ascofuranone on cultured T. b. brucei
Because ubiquinone is an essential component of the
glycerol-3-phosphate oxidase system, we searched for com-
pounds with a structure similar to ubiquinone that might
inhibit the respiratory chain of the LS trypanosome.We found
ascofuranone, a potent and specific inhibitor of glucose-
dependent respiration in cultured cells and of the glycerol-
3-phosphate oxidase from isolated mitochondria (Fig. 3) [3].
Ascofuranone is isolated from phytopathogenic fungus,
Ascochyta visiae [13]. This compound possesses host-medi-
ated anti-tumor activity because it activates macrophages
[14]. This appears to be due to the respiratory inhibition of
macrophages via the quinone site [15]. Therefore, we
examined the effect of ascofuranone on the respiration of
cultured trypanosomes to determine if it might inhibit the
glycerol-3-phosphate oxidase system. Surprisingly, we
found that nanomolar concentrations of ascofuranone inhibit
mitochondrial glycerol-3-phosphate dependent oxidase
activity as well as glucose-dependent respiration of cultured
cells [3]. In contrast, micromolar concentrations of ascofur-
anone are required for inhibition of mitochondria from other
organisms. At least, one of the targets of this compound
seems to be TAO because it potently inhibited mitochon-
drial quinol oxidase activity (Ki = 2.38 nM). This value is
three orders of magnitude lower than that of suramin
(Ki = 4.1 AM) and n-propyl gallate (Ki = 6.3 AM) [11,16],
suggesting that ascofuranone is a specific inhibitor of the
oxidase system. Because 4-O-methoxycarbonylmethyl and
4-O-carboxymethyl-substitutions (Fig. 3) decrease its effect
dramatically, the 4-OH group of the compound likely plays
an important role in the inhibitory mechanism [3]. Finally,
in vitro growth of the LS form of the trypanosome is also
inhibited by ascofuranone.
Fig. 2. Glycerol-3-phosphate oxidase system in T. b. brucei mitochondria. This system oxidizes glycerol-3-phosphate produced in the glycosomes using the
electron transport system consisting of glycerol-3-phosphate dehydrogenase, ubiquinone, and cyanide-insensitive alternative oxidase (TAO) localized in the
mitochondrial inner membrane.
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3.2. Effect of ascofuranone on mice infected with T. b. brucei
Ascofuranone is not only a potent inhibitor in vitro, but it
also is an effective chemotherapeutic agent for the treatment
of African trypanosomiasis in mice with a high level of
parasitemia [4]. Combination of 3 g/kg glycerol with either
oral (100 mg/kg) or intraperitoneal (25 mg/kg) ascofuranone
provided dramatic antitrypanosomal activity in infected
mice. In fact, all trypanosomes disappeared within 30 min
of intraperitoneal treatment and within 180 min after oral
administration.
The efficacy of oral treatment is an extremely important
factor for practical use of ascofuranone because a simple
mode of administration is essential in rural conditions.
Presently, all drugs available for human and animal trypano-
somiasis are administered intramuscularly (pentamidine,
diminazene aceturate and isometamidium chloride) or intra-
venously (suramin, melarsoprol and DFMO) [7]. In addition,
our recent studies in rat and human cell lines show that
ascofuranone has desirable pharmacokinetic properties, is
safe, and is without any side effect (Hosokawa, unpublished
observation).
4. TAO as a target of ascofuranone
4.1. Alternative oxidase (AOX)
As described in the previous section, TAO appears to be
at least one of the sites of inhibition in the glycerol-3-
phosphate oxidase system of LS form mitochondria. This
Fig. 4. Two proposed models of AOX and inhibition by ascofuranone. (left) Transmembrane model proposed by Siedow et al. [27], (right) interfacial
membrane model proposed by Andersson and Nordlund [28].
Fig. 3. Ascofuranone and its derivatives.
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terminal oxidase is completely different in structure than the
cyanide-sensitive mammalian type cytochrome c oxidase
found in the mitochondria of the procyclic trypanosome
forms. Like other forms of AOX, TAO is thought to contain
iron rather than heme as the prosthetic group. Chaudhuri et
al. [17] showed by cDNA analysis that TAO belongs to the
AOX family of mitochondrial oxidase of higher plants,
algae, yeast, slim molds, and free-living amoebae. TAO
and AOX have many characteristics in common, including:
(1) they possess a cyanide-insensitive ubiquinol oxidase
activity; (2) both enzymes are specifically inhibited by
SHAM and n-propyl gallate; (3) they are mitochondrial
inner membrane proteins containing four a-helices and with
a mass of 30–38 kDa (Fig. 4); (4) like ribonucleotide
reductase R2 and methane monooxygenase, they have a
catalytic site containing a putative binuclear iron center
coordinated by two helices that include a Glu–X–X–
His motif as well as two helices with a conserved Glu
or Asp residue; (5) TAO cross-reacts with an anti-plant
AOX monoclonal antibody recognizing the region
(RADEXXHXXXNH), which contains the C-terminal
iron-bound motif [18].
In plant AOX, there is a conserved Cys residue close to
the N-terminus, and the disulfhydryl-bound dimer has low
activity. The activity increases when an a-keto acid is bound
to the sulfhydryl group of the reduced monomer by a
thiohemiacetal linkage [19]. In contrast, in amoebae, algae,
and yeast, AOX is activated by purine nucleotides such as
AMP and GMP [20]. However, these studies were per-
formed using intact cells or mitochondria, because the
purified enzyme is very labile. The same problem has
limited the study of TAO from trypanosomes.
4.2. TAO
Because TAO is a unique enzyme in trypanosome LS
form, and may be a good target for anti-trypanosome
chemotherapy, many studies have examined the effects of
TAO electron transport inhibitors. SHAM and n-propyl
gallate, inhibitors of plant AOX with a benzene ring-like
ubiquinone, inhibit TAO [16,21]. Structure–function rela-
tionships of p-alkyloxybenzhydroxaminc acid and of 3,4-
dihydroxybenzoic acid, have been studied in detail [16,22].
Alkyl esters of 3,4-dihydroxybenzoic acid inhibit the glyc-
erol-3-phosphate oxidase system at concentration 400-fold
lower than that needed for inhibition by SHAM. However,
no drug has been developed from these compounds because
of their low solubility and selectivity.
Clearly, understanding the function of TAO is essential for
developing new inhibitors. Chaudhuri et al. [23] partially
purified TAO from NP-40-solubilized mitochondria. The
specific activity of TAO increased 10-fold by gel filtration,
and a 33-kDa peptide was identified as TAO, but no further
information could be obtained due to its low stability and
recovery. To solve this problem, TAO has been expressed in
an E. coli heme synthesis mutant lacking a functional
terminal oxidase such as cytochrome bo and bd complexes.
In this system, TAO restores respiration, but the amount of
recombinant enzyme produced is not enough for biochemical
analyses.
Recently, we have established a system for over-express-
ing TAO in E. coli using pET expression vector [24]. TAO-
expressing E. coli are easily identified because they are
resistant to cyanide. Further, the respiratory activity of their
cell membranes is also cyanide-insensitive. In addition, the
Fig. 5. Amino acid sequences of cDNA for TAO from two strains of T. b. brucei. Amino acid sequences of TAO from T. b. brucei strain TC221 (present study,
the accession number AB070617 in DDBJ) and EATRO110 [25] are compared. (*) Identical amino acid; (arrows) conserved di-iron coordination motif (–E–
and –EXXH–).
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respiratory activity is sensitive to ascofuranone, which does
not inhibit E. coli terminal oxidases. This system, therefore,
allows detailed analysis of TAO. Indeed, enzymological
analysis using the recombinant TAO revealed that the
inhibitory effect of ascofuranone is due to competitive
inhibition for ubiquinone, suggesting that the quinone ring
structure is closely involved in the inhibition mechanism
(Fukai et al., unpublished results).
During the establishment of the E. coli expression system
for TAO, we found strain-specific differences in TAO’s
amino acid sequence (Fig. 5). The C-terminal part of TAO
from the strain that we are using, T. b. brucei TC221, is
considerably different than that cloned by Hill’s group from
the EATRO110 strain [25]. Further, the amino acid sequence
of TC221 TAO is much more closer than EATRO110 TAO
to other forms of AOX. Both forms of TAO contained the
conserved diiron-coordination motif, consistent with the
ability of both TAO cDNAs to restore of respiration of an
E. coli heme synthesis mutant. Comparative analysis of
these two enzymes, including sensitivity to ascofuranone,
may reveal structure–function relationship of TAO and
provide insight into its mechanism of inhibition.
5. Conclusions and perspectives
As described in this review, the parasite metabolic system
is an attractive target for chemotherapy because it is different
than the host metabolic system and because it is essential for
parasite survival. TAO in trypanosome mitochondria and its
specific inhibitor, ascofuranone are excellent examples in this
regard. As pointed out by Opperdoes [9], ascofuranone is the
most potent TAO inhibitor to date. Because of its high
selectivity and low toxicity, ascofuranone is a potential
candidate for the next generation of anti-trypanosomal
agents. Indeed, current studies are examining the molecular
mechanism of ascofuranone and ways of improving its
efficacy in vivo.
One problem that must be solved is that glycerol must be
administered along with ascofuranone, to inhibit the reverse
reaction of glycerol kinase (see Fig. 1). Although glycerol is
not toxic, it is not practical to give the large dose (3 g/kg)
required, and an inhibitor of the reverse reaction of glycerol
kinase is expected to be more useful. Fortunately, glycerol
kinase has been cloned and the recombinant enzyme can be
over-expressed [26]. In addition, studies on glycerol kinase
from trypanosomastids that lack or have a limited capacity
to produce glycerol, such as T. vivax and T. congolense, will
provide useful information on the glycerol kinase enzyme.
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